Interview with CEO Richard Jagger on The Constant Investor, page-9

agree, its one of those where the market size is in many billions, and a new effective product IP against resistant strains could have significant penetration.

It certainly has wow factor, and i think coming off its 20c IPO, the loyalty option issue, they just need to get their message/ story a little further afoot.

So early stage and everything, and will march forwards with their efforts, but if they can be effective to treat existing resistant insects, via new means....huge opportunity and will probably get taken over for a healthy premium.

"Bio-Gene Technology Limited (ASX: BGT, “Bio-Gene” or “the Company”), an agtech development company enabling the next generation of novel insecticides to address insecticide resistance, has successfully completed initial toxicology studies in acute and seven-day repeated dose testing of flavesone with positive results demonstrating a favourable safety profile.

Flavesone is the active constituent contained in the products being developed under the Flavocide™ brand. The favourable safety profile demonstrated in short term toxicity data will now enable the commencement of longer term, 28-day oral and dermal toxicity studies with an international regulatory accredited toxicology testing organisation.

“The findings from the acute and seven-day toxicology studies indicate that flavesone has a high safety threshold and we are excited to be able to initiate longer term studies today which will form part of our future registration filings,” said Richard Jagger, Bio-Gene’s CEO-elect. “As well as demonstrating product efficacy, a critical part of registering any new insecticide is to demonstrate that it is safe to mammals at expected exposure rates. Our initial results, which we now need to confirm in longer term studies, indicate that Flavocide™ will meet this requirement.”